A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

• Status: Completed
• Trial end date: 2021-03-31
• Target enrollment: 0
• Participant gender: All

Summary

According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide inhalation could eradicate SARS-CoV-2 compared to standard supportive care in patients with mild COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea University Guro Hospital
• Treatments: Ciclesonide; Hydroxychloroquine

Criteria

Inclusion Criteria:

• Patients with mild COVID-19 (NEWS scoring system 0-4)

• Patient within 7 days from symptom onset or Patient within 48 hous after laboratory diagnosis (SARS-CoV-2 RT-PCR)

Exclusion Criteria:

• Hypoxia (SaO2 <95%)

• Unable to take oral medication

• Unable to use inhaler

• Pregnancy or breast feeding

• Immunocompromising conditions

• Moderate/severe renal dysfunction : creatinine clearance (CCL) < 30 mL/min

• Moderate/severe liver dysfunction: AST or ALT > 5 times upper normal limit

• Asthma or chronic obstructive lung disease